FIG. 4.

Broad antitumor activity of ZD55-TRAIL-IETD-Smac in vitro. (A) Human cancer cell lines (Bel-7404, NCI-H460, HeLa, Bcap37, SW620, and Huh-7) and normal human cell lines (QSG-7701 and WI38) were infected with ZD55, ZD55-TRAIL, ZD55-Smac, and ZD55-TRAIL-IETD-Smac at an MOI of 10 or with ZD55-TRAIL combined with ZD55-Smac at an MOI of 5. On days 1, 2, 3, and 4 postinfection, cell viability was examined by MTT colorimetric assay. Data shown (means±SD) are representative of three experiments. (B) Tumor cells (Bel-7404, Huh-7, PLC, and SW620) and normal human cells (WI38 and QSG-7701) were seeded in 24-well plates at a density of 5×10⁴ cells per well and infected with various oncolytic adenoviruses at a series of MOIs. In combination therapy, ZD55-TRAIL and ZD55-Smac were used at a corresponding half-dose. Six days later, cells were stained with crystal violet. Color images available online at www.liebertpub.com/hum